Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomx Ltd (PHGE)

Biomx Ltd (PHGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,669
  • Shares Outstanding, K 1,526
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,730 K
  • EBIT $ -33 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.61
  • Number of Estimates 1
  • High Estimate -4.61
  • Low Estimate -4.61
  • Prior Year -20.34
  • Growth Rate Est. (year over year) +77.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +97.24%
on 12/31/25
3.82 -6.54%
on 01/22/26
+1.38 (+63.01%)
since 12/22/25
3-Month
1.50 +137.94%
on 12/16/25
11.88 -69.94%
on 10/23/25
-7.03 (-66.33%)
since 10/22/25
52-Week
1.50 +137.94%
on 12/16/25
22.06 -83.81%
on 02/24/25
-10.39 (-74.43%)
since 01/22/25

Most Recent Stories

More News
BiomX Announces $3.0 Million Private Placement

NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...

PHGE : 3.57 (+16.67%)
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in...

PHGE : 3.57 (+16.67%)
BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in...

PHGE : 3.57 (+16.67%)
BiomX Inc. Announces 1-for-19 Reverse Stock Split

NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...

PHGE : 3.57 (+16.67%)
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior Phase 2 success  BiomX expects FDA feedback on BX004...

PHGE : 3.57 (+16.67%)
BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...

PHGE : 3.57 (+16.67%)
BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections

NESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...

PHGE : 3.57 (+16.67%)
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications...

PHGE : 3.57 (+16.67%)
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria,...

PHGE : 3.57 (+16.67%)
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification...

PHGE : 3.57 (+16.67%)

Business Summary

BiomX Ltd is a clinical stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy bacteria which affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC and cancer. BiomX Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 4.85
2nd Resistance Point 4.34
1st Resistance Point 3.95
Last Price 3.57
1st Support Level 3.05
2nd Support Level 2.54
3rd Support Level 2.15

See More

52-Week High 22.06
Fibonacci 61.8% 14.20
Fibonacci 50% 11.78
Fibonacci 38.2% 9.35
Last Price 3.57
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar